Interim Report for the period April – June 2022
FDA grants priority review for lecanemab marketing application Events during the second quarter 2022 · Eisai completed the rolling submission of lecanemab for treatment of early Alzheimer’s disease to the US Food and Drug Administration (FDA) under the accelerated approval pathway · AbbVie took a strategic business decision to terminate its collaboration with BioArctic regarding its alpha-synuclein projects in Parkinson’s disease. BioArctic is now working with AbbVie to bring back the projects with the intention of finding a new partner Events after the second quarter